Research Analysts Offer Predictions for ABVX FY2025 Earnings

ABIVAX Société Anonyme (NASDAQ:ABVX) – Equities researchers at Lifesci Capital issued their FY2025 EPS estimates for shares of ABIVAX Société Anonyme in a research note issued on Tuesday, March 25th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings of ($3.14) per share for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share.

Other analysts have also recently issued research reports about the company. JMP Securities reiterated a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $38.00.

ABIVAX Société Anonyme Stock Down 3.8 %

ABIVAX Société Anonyme stock opened at $6.82 on Wednesday. ABIVAX Société Anonyme has a 12-month low of $5.50 and a 12-month high of $16.63. The company has a fifty day simple moving average of $6.79 and a 200-day simple moving average of $8.41.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of large investors have recently added to or reduced their stakes in ABVX. BNP Paribas Financial Markets raised its holdings in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the last quarter. Walleye Capital LLC boosted its position in ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after acquiring an additional 80,807 shares during the last quarter. Point72 Asset Management L.P. grew its stake in ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after acquiring an additional 119,300 shares during the period. GAMMA Investing LLC acquired a new position in ABIVAX Société Anonyme in the 4th quarter valued at $29,000. Finally, R Squared Ltd acquired a new stake in shares of ABIVAX Société Anonyme during the fourth quarter worth $36,000. 47.91% of the stock is owned by institutional investors and hedge funds.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.